Skip to Main content Skip to Navigation
Conference papers

OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial

Dominique Salmon-Céron 1, 2, * Christine Durier 3 Corinne Desaint 1 Lise Cuzin 4 Mathieu Surénaud 5 yvette Hénin 1 Jean-Daniel Lelièvre 6 B Bonnet 7 Gilles Pialoux 8 Isabelle Poizot-Martin 9 Nadine Ben Hamouda 5 Angéla Jackson 5 C Flys 5 Christine Guérin 1 Jean-Pierre Aboulker 3 Jeannine Choppin 5 Odile Launay 1 
* Corresponding author
1 CIC - Biotherapie - AP-HP (cochin - Pasteur)
2 Hôpital Cochin [AP-HP]
3 Essais Therapeutiques et Infection Par Le Vih
4 CHU Toulouse [Toulouse]
5 UMR_S567 / UMR 8104 - Institut Cochin
6 Hôpital Henri Mondor
7 Hôpital Hôtel-Dieu
8 CHU Tenon [AP-HP]
9 Hôpital Saint-Marguerite
Résumé : n.a
Document type :
Conference papers
Complete list of metadata
https://www.hal.inserm.fr/inserm-00663582
Contributor : Ed. BMC Connect in order to contact the contributor
Submitted on : Friday, January 27, 2012 - 1:19:34 PM
Last modification on : Sunday, June 26, 2022 - 11:55:22 AM
Long-term archiving on: : Saturday, April 28, 2012 - 2:26:33 AM

Files

Vignette du document
1742-4690-6-S3-O25.pdf
Publisher files allowed on an open archive

Identifiers

Collections

INSERM | UNIV-PARIS5 | UPEC-UPEM | CNRS | UPEC | SORBONNE-UNIVERSITE | SU-MEDECINE | UNIV-PARIS | UP-SANTE | SU-TI

Citation

Dominique Salmon-Céron, Christine Durier, Corinne Desaint, Lise Cuzin, Mathieu Surénaud, et al.. OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial. AIDS Vaccine 2009, Oct 2009, Paris, France. pp.O25, ⟨10.1186/1742-4690-6-S3-O25⟩. ⟨inserm-00663582⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

181

Files downloads

174